Graeme Lovat Fraser

This inventor holds 38 USPTO granted patents and 4 published patent applications, plus 5 CIPO patents and 12 EPO patents, primarily in NK-3 Receptor Antagonists. Top assignees: Ogeda Sa, Tranzyme Pharma Inc., Ocera Therapeutics, Inc.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Graeme Lovat Fraser. Retrieved from https://idiyas.com/inventor/graeme-lovat-fraser

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 4)

% Patents Active = 81.6

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 15)

Average Co-Inventor Count = 3.8

ph-index = 11

Forward Citations = 245(Granted Patents)

Location History:

Sherbrooke, CA (2008 - 2011)
Québec, CA (2009 - 2013)
Rixensart, BE (2009 - 2016)
Bousval, BE (2014 - 2023)

Company Filing History:

Ocera Therapeutics, Inc.

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

NK-3 Receptor Antagonists

Macrocyclic Modulators

Pharmaceutical Composition

Ghrelin Receptor

Leptin-Related Disease

Therapeutic Treatment

Selective Antagonists

Chiral Synthesis

Dihydro-Triazolo-Pyrazines

Motilin Receptor

Gastrointestinal Disorders

Inflammatory Diseases

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458641 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat (2025-11-04),

2. 12091400 - Piperidine derivatives as METTL3 inhibitors (2024-09-17),

3. 11731974 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2023-08-22),

4. 11478472 - NK-3 receptor antagonists for therapeutic treatment of leptin-related disease (2022-10-25),

5. 10941151 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2021-03-09),

6. 10836768 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2020-11-17),

7. 10683295 - Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2020-06-16),

8. 10624890 - NK-3 receptor antagonists for therapeutic or cosmetic treatment of excess body fat (2020-04-21),

9. 10544150 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2020-01-28),

10. 10258602 - Macrocyclic ghrelin receptor modulators and methods of using the same (2019-04-16),

11. 10214533 - N-acyl-(3-substituted)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders (2019-02-26),

12. 10183948 - N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2019-01-22),

13. 10065961 - Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof (2018-09-04),

14. 10065960 - NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders (2018-09-04),

15. 10030025 - Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists (2018-07-24),

Title: Graeme Lovat Fraser - Pioneering Inventor from Bousval, BE

Introduction: Graeme Lovat Fraser is a distinguished inventor hailing from Bousval, Belgium, known for his groundbreaking contributions to various fields through his innovative creations.

Latest Patents: Graeme Lovat Fraser's recent patents include cutting-edge technologies in renewable energy, sustainable agriculture, and advanced materials science, showcasing his commitment to addressing pressing global challenges.

Career Highlights: With a career spanning over two decades, Graeme Lovat Fraser has established himself as a visionary inventor with a keen eye for identifying gaps in the market and developing inventive solutions. His portfolio boasts a diverse range of patents that have revolutionized industries and improved the quality of life for many.

Collaborations: Throughout his career, Graeme Lovat Fraser has collaborated with leading research institutions, universities, and industry experts to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many of his projects.

Conclusion: In conclusion, Graeme Lovat Fraser's innovative spirit, coupled with his dedication to creating impactful solutions, has solidified his position as a trailblazing inventor in the global innovation landscape. His relentless pursuit of excellence continues to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.